Cargando…
Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial
Background: In perioperative pain control, adjuvants such as lidocaine can reduce opioid consumption in a specific type of surgery. The aim of this single-center prospective double-blinded randomized controlled trial was to determine opioid consumption in the perioperative period in patients receivi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053864/ https://www.ncbi.nlm.nih.gov/pubmed/36983312 http://dx.doi.org/10.3390/jcm12062312 |
_version_ | 1785015514385350656 |
---|---|
author | Gajniak, Dariusz Mendrala, Konrad Cyzowski, Tomasz Polak, Michał Gierek, Danuta Krzych, Łukasz J. |
author_facet | Gajniak, Dariusz Mendrala, Konrad Cyzowski, Tomasz Polak, Michał Gierek, Danuta Krzych, Łukasz J. |
author_sort | Gajniak, Dariusz |
collection | PubMed |
description | Background: In perioperative pain control, adjuvants such as lidocaine can reduce opioid consumption in a specific type of surgery. The aim of this single-center prospective double-blinded randomized controlled trial was to determine opioid consumption in the perioperative period in patients receiving continuous lidocaine infusion. Methods: Patients undergoing elective abdominal aorta and/or iliac arteries open surgery were randomized into two groups to receive 1% lidocaine or placebo at the same infusion rate based on ideal body weight (bolus of 0.15 mL/kg during the induction of anesthesia followed by continuous infusion of 0.2 mL/kg/h during surgery; postoperatively 0.1 mL/kg/h for 24 h) additionally to standard opioid analgesia. Results: Total opioid consumption within 24 h after surgery was 89.2 mg (95%CI 80.9–97.4) in the lidocaine and 113.1 mg (95%CI 102.5–123.6) in the placebo group (p = 0.0007). Similar findings were observed in opioid consumption intraoperatively (26.7 mg (95%CI 22.2–31.3) vs. 35.1 mg (95%CI 29.1–41.2), respectively, p = 0.029) and six hours postoperatively (47.5 mg (IQR 37.5–59.5) vs. 60 mg (IQR 44–83), respectively, p = 0.01). Conclusions: In high-risk vascular surgery, lidocaine infusion as an adjunct to standard perioperative analgesia is effective. It may decrease opioid consumption by more than 20% during the first 24 h after surgery, with no serious adverse effects noted during the study period. |
format | Online Article Text |
id | pubmed-10053864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100538642023-03-30 Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial Gajniak, Dariusz Mendrala, Konrad Cyzowski, Tomasz Polak, Michał Gierek, Danuta Krzych, Łukasz J. J Clin Med Article Background: In perioperative pain control, adjuvants such as lidocaine can reduce opioid consumption in a specific type of surgery. The aim of this single-center prospective double-blinded randomized controlled trial was to determine opioid consumption in the perioperative period in patients receiving continuous lidocaine infusion. Methods: Patients undergoing elective abdominal aorta and/or iliac arteries open surgery were randomized into two groups to receive 1% lidocaine or placebo at the same infusion rate based on ideal body weight (bolus of 0.15 mL/kg during the induction of anesthesia followed by continuous infusion of 0.2 mL/kg/h during surgery; postoperatively 0.1 mL/kg/h for 24 h) additionally to standard opioid analgesia. Results: Total opioid consumption within 24 h after surgery was 89.2 mg (95%CI 80.9–97.4) in the lidocaine and 113.1 mg (95%CI 102.5–123.6) in the placebo group (p = 0.0007). Similar findings were observed in opioid consumption intraoperatively (26.7 mg (95%CI 22.2–31.3) vs. 35.1 mg (95%CI 29.1–41.2), respectively, p = 0.029) and six hours postoperatively (47.5 mg (IQR 37.5–59.5) vs. 60 mg (IQR 44–83), respectively, p = 0.01). Conclusions: In high-risk vascular surgery, lidocaine infusion as an adjunct to standard perioperative analgesia is effective. It may decrease opioid consumption by more than 20% during the first 24 h after surgery, with no serious adverse effects noted during the study period. MDPI 2023-03-16 /pmc/articles/PMC10053864/ /pubmed/36983312 http://dx.doi.org/10.3390/jcm12062312 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gajniak, Dariusz Mendrala, Konrad Cyzowski, Tomasz Polak, Michał Gierek, Danuta Krzych, Łukasz J. Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title | Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title_full | Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title_fullStr | Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title_full_unstemmed | Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title_short | Efficacy of Lidocaine Infusion in High-Risk Vascular Surgery—A Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial |
title_sort | efficacy of lidocaine infusion in high-risk vascular surgery—a randomized, double-blind, placebo-controlled single-center clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053864/ https://www.ncbi.nlm.nih.gov/pubmed/36983312 http://dx.doi.org/10.3390/jcm12062312 |
work_keys_str_mv | AT gajniakdariusz efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial AT mendralakonrad efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial AT cyzowskitomasz efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial AT polakmichał efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial AT gierekdanuta efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial AT krzychłukaszj efficacyoflidocaineinfusioninhighriskvascularsurgeryarandomizeddoubleblindplacebocontrolledsinglecenterclinicaltrial |